^
Association details:
| Biomarker: | BCR-ABL1 L387F |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Bosulif (bosutinib) (Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Excerpt:
Among the 115 patients with known mutations at baseline, the most common were M351T (n = 7), F359V (n = 7), F317L (n = 4), L248V (n = 4), G250E (n = 3), M244V (n = 3), and T315I (n = 3). Similar rates of CHR or MCyR were observed between patients with and without mutations. Responses were observed broadly across Bcr-Abl mutants, except for T315I (Figure 3 and supplemental Table 3).
DOI:
https://dx.doi.org/10.1182%2Fblood-2011-05-355594
Trial ID:
Source:
Title:
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
Excerpt:
Responses were seen across Bcr-Abl mutations, including those associated with dasatinib and nilotinib resistance, except T315I. Bosutinib had an acceptable safety profile; treatment-emergent adverse events were primarily manageable grade 1/2 gastrointestinal events and rash. Grade 3/4 nonhematologic adverse events (> 2% of patients) included diarrhea (8%) and rash (4%). Bosutinib may offer a new treatment option for patients with chronic-phase CML after treatment with multiple TKIs. Table 4.....
DOI:
https://doi.org/10.1182/blood-2011-11-390120
Trial ID:
